Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 15;22(2):87-98.
doi: 10.1631/jzus.B2000479.

Comparison of COVID-19 and influenza characteristics

Affiliations
Review

Comparison of COVID-19 and influenza characteristics

Yu Bai et al. J Zhejiang Univ Sci B. .

Abstract

The emergence of coronavirus disease 2019 (COVID-19) not only poses a serious threat to the health of people worldwide but also affects the global economy. The outbreak of COVID-19 began in December 2019, at the same time as the influenza season. However, as the treatments and prognoses of COVID-19 and influenza are different, it is important to accurately differentiate these two different respiratory tract infections on the basis of their respective early-stage characteristics. We reviewed official documents and news released by the National Health Commission of the People's Republic of China, the Chinese Center for Disease Control and Prevention (China CDC), the United States CDC, and the World Health Organization (WHO), and we also searched the PubMed, Web of Science, Excerpta Medica database (Embase), China National Knowledge Infrastructure (CNKI), Wanfang, preprinted bioRxiv and medRxiv databases for documents and guidelines from earliest available date up until October 3rd, 2020. We obtained the latest information about COVID-19 and influenza and summarized and compared their biological characteristics, epidemiology, clinical manifestations, pathological mechanisms, treatments, and prognostic factors. We show that although COVID-19 and influenza are different in many ways, there are numerous similarities; thus, in addition to using nucleic acid-based polymerase chain reaction (PCR) and antibody-based approaches, clinicians and epidemiologists should distinguish between the two using their respective characteristics in early stages. We should utilize experiences from other epidemics to provide additional guidance for the treatment and prevention of COVID-19.

Keywords: Coronavirus disease 2019 (COVID-19); Influenza; Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

PubMed Disclaimer

Similar articles

Cited by

References

    1. Ayerbe L, Risco-Risco C, Ayis S, 2020. The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients. Intern Emerg Med, 15(8): 1501-1506. 10.1007/s11739-020-02505-x - DOI - PMC - PubMed
    1. Bennett JE, Dolin R, Blaser MJ, 2015. Mandell, Douglas, and Bennett’s Principles and Practice of Infectious Diseases, 8th Ed Elsevier, Philadelphia, USA: 10.1016/C2012-1-00075-6 - DOI
    1. Bloch EM, Shoham S, Casadevall A, et al. , 2020. Deployment of convalescent plasma for the prevention and treatment of COVID-19. J Clin Invest, 130(6): 2757-2765. 10.1172/JCI138745 - DOI - PMC - PubMed
    1. Bonmarin I, Belchior E, Bergounioux J, et al. , 2015. Intensive care unit surveillance of influenza infection in France: the 2009/10 pandemic and the three subsequent seasons. Euro Surveill, 20(46): 30066 10.2807/1560-7917.ES.2015.20.46.30066 - DOI - PubMed
    1. Brun-Buisson C, Richard JCM, Mercat A, et al. , 2011. Early corticosteroids in severe influenza A/H1N1 pneumonia and acute respiratory distress syndrome. Am J Respir Crit Care Med, 183(9): 1200-1206. 10.1164/rccm.201101-0135OC - DOI - PubMed